Home LiteratureArticle Details
PMID: 18987634 Published · ppublish English Journal Article Review

The impact of O2 availability on human cancer.

Nature reviews. Cancer ·Vol. 8 ·No. 12 ·2008-12-00 ·Pages 967-75

Bertout JA, Patel SA, Simon MC

Abstract

During the past century it has been established that regions within solid tumours experience mild to severe O(2) deprivation owing to aberrant vascular function. These hypoxic regions are associated with altered cellular metabolism, as well as increased resistance to radiation and chemotherapy. As discussed in this Timeline, over the past decade work from many laboratories has elucidated the mechanisms by which hypoxia-inducible factors (HIFs) modulate tumour cell metabolism, angiogenesis, growth and metastasis. The central role played by intra-tumoural hypoxia and HIF in these processes has made them attractive therapeutic targets in the treatment of multiple human malignancies.

MeSH Terms
Aerobiosis Animals Basic Helix-Loop-Helix Transcription Factors/physiology Cell Division Cell Hypoxia/physiology Glycolysis Humans Models, Animal Necrosis Neoplasms/metabolism,pathology Oxygen Consumption
Chemicals
Basic Helix-Loop-Helix Transcription Factors
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Bertout Jessica A
Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Patel Shetal A
Simon M Celeste
References (150)
150 references, click to expand
  1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    N Engl J Med. 2004 Jun 3;350(23):2335-42 PMID: 15175435
  2. Modulating the radiation response.
    Stem Cells. 1996 Jan;14(1):10-5 PMID: 8820945
  3. HIF-1 as a target for drug development.
    Nat Rev Drug Discov. 2003 Oct;2(10):803-11 PMID: 14526383
  4. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Nature. 1999 May 20;399(6733):271-5 PMID: 10353251
  5. Radiobiologic basis of oxygen as a modifying factor in radiation therapy.
    Am J Roentgenol Radium Ther Nucl Med. 1961 May;85:803-15 PMID: 13708070
  6. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse.
    J Am Coll Cardiol. 2005 Dec 6;46(11):2116-24 PMID: 16325051
  7. On the origin of cancer cells.
    Science. 1956 Feb 24;123(3191):309-14 PMID: 13298683
  8. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
    Cancer Res. 2007 May 1;67(9):4157-63 PMID: 17483326
  9. DEMONSTRATION OF AN ANOXIC COMPONENT IN A MOUSE TUMOR-CELL POPULATION BY IN VIVO ASSAY OF SURVIVAL FOLLOWING IRRADIATION.
    Radiology. 1964 Aug;83:328-36 PMID: 14207425
  10. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.
    Genes Dev. 2002 Jun 15;16(12):1466-71 PMID: 12080085
  11. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
    Science. 2001 Apr 20;292(5516):468-72 PMID: 11292861
  12. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential.
    J Nucl Med. 1997 Jul;38(7):1155-60 PMID: 9225812
  13. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
    Nat Med. 2006 Jan;12(1):122-7 PMID: 16341243
  14. The radiobiology of human cells and tissues. In vitro radiosensitivity. The picture has changed in the 1980s.
    Int J Radiat Biol. 1989 Nov;56(5):525-37 PMID: 2573641
  15. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype.
    Cancer Cell. 2006 Nov;10(5):413-23 PMID: 17097563
  16. Induction of glucose-regulated proteins during anaerobic exposure and of heat-shock proteins after reoxygenation.
    Proc Natl Acad Sci U S A. 1984 Aug;81(15):4843-7 PMID: 6589630
  17. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    J Biol Chem. 2000 Aug 18;275(33):25733-41 PMID: 10823831
  18. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation.
    Nat Med. 1997 Feb;3(2):177-82 PMID: 9018236
  19. High-pressure oxygen and radiotherapy.
    Lancet. 1955 May 28;268(6874):1091-5 PMID: 14382503
  20. Hypoxia and tumours.
    J Clin Pathol Suppl (R Coll Pathol). 1977;11:105-13 PMID: 269113
  21. Lysyl oxidase is essential for hypoxia-induced metastasis.
    Nature. 2006 Apr 27;440(7088):1222-6 PMID: 16642001
  22. Evaluation of HIF-1 inhibitors as anticancer agents.
    Drug Discov Today. 2007 Oct;12(19-20):853-9 PMID: 17933687
  23. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha.
    Mol Cell. 2007 Jan 26;25(2):207-17 PMID: 17244529
  24. Exploiting tumour hypoxia in cancer treatment.
    Nat Rev Cancer. 2004 Jun;4(6):437-47 PMID: 15170446
  25. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway.
    J Biol Chem. 1999 Mar 5;274(10):6519-25 PMID: 10037745
  26. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.
    Br J Cancer. 2001 Sep 14;85(6):881-90 PMID: 11556841
  27. Activation of the HIF pathway in cancer.
    Curr Opin Genet Dev. 2001 Jun;11(3):293-9 PMID: 11377966
  28. HIF-1alpha is essential for myeloid cell-mediated inflammation.
    Cell. 2003 Mar 7;112(5):645-57 PMID: 12628185
  29. Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia.
    Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1263-7 PMID: 3017905
  30. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells.
    Radiat Res. 1987 Aug;111(2):292-304 PMID: 3628717
  31. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis.
    Cancer. 2001 Jul 1;92(1):165-71 PMID: 11443623
  32. A conserved family of prolyl-4-hydroxylases that modify HIF.
    Science. 2001 Nov 9;294(5545):1337-40 PMID: 11598268
  33. Clinical trials of radiosensitizers: what should we expect?
    Int J Radiat Oncol Biol Phys. 1984 Mar;10(3):425-9 PMID: 6231272
  34. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
    J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 PMID: 11181778
  35. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
    Science. 2001 Apr 20;292(5516):464-8 PMID: 11292862
  36. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.
    Science. 1999 Apr 16;284(5413):455-61 PMID: 10205047
  37. Role of hypoxia-inducible factor in cell survival during myocardial ischemia-reperfusion.
    Cell Death Differ. 2008 Apr;15(4):686-90 PMID: 18259200
  38. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.
    Cancer Cell. 2002 Jun;1(5):459-68 PMID: 12124175
  39. Oxygen regulated 80 kDa protein and glucose regulated 78kDa protein are identical.
    Mol Cell Biochem. 1991 May 15;103(2):141-8 PMID: 1712895
  40. Production of metastases by a primary tumour irradiated under aerobic and anaerobic conditions in vivo.
    Br J Cancer. 1972 Oct;26(5):402-12 PMID: 5085679
  41. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer.
    Cancer Res. 2000 Sep 1;60(17):4693-6 PMID: 10987269
  42. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment.
    Cancer Metastasis Rev. 2007 Jun;26(2):241-8 PMID: 17440683
  43. Sorafenib in advanced clear-cell renal-cell carcinoma.
    N Engl J Med. 2007 Jan 11;356(2):125-34 PMID: 17215530
  44. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.
    Nat Med. 2004 Jun;10(6):594-601 PMID: 15156201
  45. Coordinate regulation of glycolysis by hypoxia in mammalian cells.
    J Cell Physiol. 1984 Mar;118(3):287-90 PMID: 6699103
  46. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
    Cancer Cell. 2003 Apr;3(4):347-61 PMID: 12726861
  47. Normal fibroblasts responding to anoxia exhibit features of the malignant phenotype.
    J Biol Chem. 1989 Sep 5;264(25):14885-92 PMID: 2768244
  48. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies.
    Radiother Oncol. 1991;20 Suppl 1:13-9 PMID: 2020762
  49. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy.
    Clin Cancer Res. 2001 Jun;7(6):1661-8 PMID: 11410504
  50. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells.
    Proc Natl Acad Sci U S A. 1988 Dec;85(24):9533-7 PMID: 3200838
  51. Enhancer element at the 3'-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene.
    J Biol Chem. 1991 Aug 25;266(24):15563-6 PMID: 1874713
  52. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression.
    Cancer Res. 2007 Jan 15;67(2):563-72 PMID: 17234764
  53. Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling.
    Cancer Res. 2003 Apr 15;63(8):1865-70 PMID: 12702575
  54. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis.
    J Clin Invest. 2007 Dec;117(12):3879-89 PMID: 17992257
  55. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs.
    FASEB J. 2003 Feb;17(2):271-3 PMID: 12490539
  56. Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse.
    Mech Dev. 1998 Apr;73(1):117-23 PMID: 9545558
  57. Tumour anoxia and the response to radiation.
    Sci Basis Med Annu Rev. 1965;:74-90 PMID: 5321384
  58. Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface.
    J Clin Invest. 1992 Dec;90(6):2333-9 PMID: 1281830
  59. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium.
    J Clin Invest. 1991 Sep;88(3):1054-7 PMID: 1885767
  60. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy.
    Br J Radiol. 1953 Dec;26(312):638-48 PMID: 13106296
  61. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours.
    Nature. 1996 Jan 4;379(6560):88-91 PMID: 8538748
  62. The in vitro sensitivity of chronically hypoxic EMT6/SF cells to X-radiation and hypoxic cell radiosensitizers.
    Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Jul;48(1):127-38 PMID: 3159699
  63. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis.
    N Engl J Med. 2008 Jan 10;358(2):162-8 PMID: 18184961
  64. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.
    J Clin Oncol. 2006 Feb 10;24(5):727-35 PMID: 16418497
  65. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension.
    Am J Physiol. 1996 Oct;271(4 Pt 1):C1172-80 PMID: 8897823
  66. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein.
    Science. 1988 Dec 9;242(4884):1412-5 PMID: 2849206
  67. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.
    Cell. 2001 Oct 5;107(1):43-54 PMID: 11595184
  68. VEGF-targeted therapy: mechanisms of anti-tumour activity.
    Nat Rev Cancer. 2008 Aug;8(8):579-91 PMID: 18596824
  69. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation.
    Mol Cell Biol. 1992 Dec;12(12):5447-54 PMID: 1448077
  70. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells.
    J Clin Invest. 1990 Aug;86(2):670-4 PMID: 2384608
  71. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression.
    Mol Cell. 2005 Mar 18;17(6):793-803 PMID: 15780936
  72. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene.
    Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10553-7 PMID: 1961720
  73. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha.
    Nature. 1998 Mar 26;392(6674):405-8 PMID: 9537326
  74. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.
    Clin Cancer Res. 2002 Jun;8(6):1831-7 PMID: 12060624
  75. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family.
    J Biol Chem. 2002 Jul 19;277(29):26351-5 PMID: 12042299
  76. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity.
    Genes Dev. 2001 Oct 15;15(20):2675-86 PMID: 11641274
  77. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species.
    FASEB J. 2003 Mar;17(3):503-5 PMID: 12514119
  78. Targeting HIF-1 for cancer therapy.
    Nat Rev Cancer. 2003 Oct;3(10):721-32 PMID: 13130303
  79. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
    Science. 2004 Jun 4;304(5676):1497-500 PMID: 15118125
  80. Tumour hypoxia: the picture has changed in the 1990s.
    Int J Radiat Biol. 1994 Jan;65(1):95-102 PMID: 7905916
  81. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha.
    J Clin Invest. 1999 Mar;103(5):691-6 PMID: 10074486
  82. Influence of oxygen tension on x-ray-induced chromosomal damage in Ehrlich ascites tumor cells irradiated in vitro and in vivo.
    Radiat Res. 1959 Jul;11(1):115-46 PMID: 13668067
  83. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation.
    Cancer Cell. 2007 Aug;12(2):108-13 PMID: 17692803
  84. OXYGENATION IN RADIOTHERAPY OF MALIGNANT DISEASE OF THE UPPER AIR PASSAGES. THE OXYGEN EFFECT OF RADIOTHERAPY.
    Proc R Soc Med. 1964 Jul;57:635-8 PMID: 14178962
  85. The effect of tissue oxygen tension on the radiosensitivity of leukaemia cells irradiated in situ in the livers of leukaemic mice.
    Br J Cancer. 1959 Dec;13:675-84 PMID: 14401598
  86. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.
    Nature. 1992 Oct 29;359(6398):843-5 PMID: 1279431
  87. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity.
    Cancer Cell. 2007 Apr;11(4):335-47 PMID: 17418410
  88. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    N Engl J Med. 2004 May 20;350(21):2129-39 PMID: 15118073
  89. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
    Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 PMID: 7539918
  90. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
    Nat Rev Drug Discov. 2004 May;3(5):391-400 PMID: 15136787
  91. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia.
    J Clin Invest. 2003 May;111(10):1519-27 PMID: 12750401
  92. Suppression of tumor growth through disruption of hypoxia-inducible transcription.
    Nat Med. 2000 Dec;6(12):1335-40 PMID: 11100117
  93. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor.
    Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13459-64 PMID: 12351678
  94. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
    Nat Cell Biol. 2000 Jul;2(7):423-7 PMID: 10878807
  95. Hypoxic radiosensitization: adored and ignored.
    J Clin Oncol. 2007 Sep 10;25(26):4066-74 PMID: 17827455
  96. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1.
    J Nucl Med. 2000 Feb;41(2):327-36 PMID: 10688119
  97. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells.
    Cancer Res. 1981 Jan;41(1):73-81 PMID: 7448778
  98. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.
    Cancer Res. 2000 Aug 1;60(15):4010-5 PMID: 10945599
  99. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1239-42 PMID: 3744945
  100. Past, present, and future of oxygen in cancer research.
    Adv Exp Med Biol. 2005;566:213-22 PMID: 16594155
  101. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.
    Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104-9 PMID: 9223322
  102. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer.
    Anticancer Res. 2000 May-Jun;20(3A):1527-33 PMID: 10928066
  103. Gadd45 and Gadd153 messenger RNA levels are increased during hypoxia and after exposure of cells to agents which elevate the levels of the glucose-regulated proteins.
    Cancer Res. 1992 Jul 1;52(13):3814-7 PMID: 1617653
  104. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
    Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10430-5 PMID: 10973499
  105. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.
    Cancer Cell. 2004 Jul;6(1):33-43 PMID: 15261140
  106. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.
    J Clin Oncol. 2000 Mar;18(6):1351-9 PMID: 10715308
  107. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients.
    Cancer Res. 2002 May 1;62(9):2493-7 PMID: 11980639
  108. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha.
    Gene Expr. 1998;7(3):205-13 PMID: 9840812
  109. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response.
    Nat Rev Cancer. 2008 Jun;8(6):425-37 PMID: 18500244
  110. Enhanced synthesis of stress proteins caused by hypoxia and relation to altered cell growth and metabolism.
    Br J Cancer. 1990 Aug;62(2):217-25 PMID: 1696830
  111. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation.
    Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9630-5 PMID: 11504942
  112. A novel technique for measuring human tissue pO2 at the cellular level.
    Br J Cancer. 1986 Sep;54(3):453-7 PMID: 3756081
  113. Oxygenation in radiotherapy. II. Clinical application.
    Br J Radiol. 1957 Aug;30(356):406-22 PMID: 13446402
  114. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.
    Mol Cell Biol. 2005 Jul;25(13):5675-86 PMID: 15964822
  115. Blood flow and tissue oxygenation of human tumors: an update.
    Adv Exp Med Biol. 1992;317:139-51 PMID: 1288121
  116. Tumor oxygenation and reoxygenation during radiation therapy: their importance in predicting tumor response.
    Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):681-5 PMID: 3700172
  117. Acute hypoxia in tumors: implications for modifiers of radiation effects.
    Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1279-82 PMID: 3759546
  118. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis.
    J Clin Invest. 2004 Oct;114(8):1098-106 PMID: 15489957
  119. Radiation plus metronidazole for glioblastoma.
    N Engl J Med. 1977 Mar 31;296(13):757 PMID: 190541
  120. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.
    Cancer Res. 2001 Apr 1;61(7):2911-6 PMID: 11306467
  121. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression.
    Nature. 2001 Nov 29;414(6863):550-4 PMID: 11734856
  122. The histological structure of some human lung cancers and the possible implications for radiotherapy.
    Br J Cancer. 1955 Dec;9(4):539-49 PMID: 13304213
  123. Persistent induction of HIF-1alpha and -2alpha in cardiomyocytes and stromal cells of ischemic myocardium.
    FASEB J. 2004 Sep;18(12):1415-7 PMID: 15247145
  124. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.
    Nature. 2003 Sep 18;425(6955):307-11 PMID: 13679920
  125. Effect of oxygen and nitric oxide on the radio-sensitivity of human cells in tissue culture.
    Nature. 1960 Jun 4;186:780-2 PMID: 13816318
  126. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes.
    J Biol Chem. 1997 Sep 5;272(36):22642-7 PMID: 9278421
  127. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis.
    Blood. 2008 Jun 1;111(11):5400-2 PMID: 18378852
  128. The identification of heme oxygenase as a major hypoxic stress protein in Chinese hamster ovary cells.
    Br J Cancer. 1991 Jul;64(1):69-73 PMID: 1854629
  129. A microRNA component of the hypoxic response.
    Cell Death Differ. 2008 Apr;15(4):667-71 PMID: 18219318
  130. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer.
    Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1192-202 PMID: 12128120
  131. Glucose metabolism by rat embryos in vitro.
    Proc Soc Exp Biol Med. 1970 Oct;135(1):51-4 PMID: 5475623
  132. Hypoxia-induced signaling in the cardiovascular system.
    Annu Rev Physiol. 2008;70:51-71 PMID: 17850210
  133. Tumor hypoxia in cancer therapy.
    Methods Enzymol. 2007;435:297-321 PMID: 17998060
  134. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene.
    Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5680-4 PMID: 2062846
  135. The effect of anoxia on tumor growth with special reference to sarcoma 180 implanted in C57 mice.
    Cancer Res. 1954 Oct;14 (9):672-6 PMID: 13209542
  136. Hypoxia and drug resistance.
    Cancer Metastasis Rev. 1994 Jun;13(2):139-68 PMID: 7923547
  137. A 24-base-pair sequence 3' to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer.
    Proc Natl Acad Sci U S A. 1993 May 1;90(9):3928-32 PMID: 8387202
  138. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.
    Genes Dev. 1997 Jan 1;11(1):72-82 PMID: 9000051
  139. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc.
    EMBO J. 2004 May 5;23(9):1949-56 PMID: 15071503
  140. The role of oxygen availability in embryonic development and stem cell function.
    Nat Rev Mol Cell Biol. 2008 Apr;9(4):285-96 PMID: 18285802
  141. Does hyperbaric oxygen have a future in radiation therapy?
    Int J Radiat Oncol Biol Phys. 1981 Aug;7(8):1125-8 PMID: 7028699
  142. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
    J Clin Oncol. 2005 Jan 1;23(1):79-87 PMID: 15625362
  143. A possible mechanism for enhancement of increased production of tumor angiogenic factor.
    Growth. 1976 Sep;40(3):205-9 PMID: 976765
  144. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway.
    Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7987-92 PMID: 9653127
  145. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch.
    Science. 2002 Feb 1;295(5556):858-61 PMID: 11823643
  146. Effects of reoxygenation on cells from hypoxic regions of solid tumors: analysis of transplanted murine tumors for evidence of DNA overreplication.
    Cancer Res. 1990 Aug 15;50(16):5031-8 PMID: 2379169
  147. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.
    Cancer. 2002 Sep 1;95(5):1055-63 PMID: 12209691
  148. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia.
    J Biol Chem. 1993 Oct 15;268(29):21513-8 PMID: 8408001
  149. Hypoxia signalling through mTOR and the unfolded protein response in cancer.
    Nat Rev Cancer. 2008 Nov;8(11):851-64 PMID: 18846101
  150. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.
    Cancer Res. 2002 Jun 15;62(12):3387-94 PMID: 12067980
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc2540
Published
2008-12-00
Epub
2008-00-06
Pages
967-75
Language
English
Region
England
NLM ID
101124168
PMCID
PMC3140692
Subset
IM
Grants
Howard Hughes Medical Institute · United States
External Links
PubMed source DOI: 10.1038/nrc2540 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2